Cargando…

Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems

In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the er...

Descripción completa

Detalles Bibliográficos
Autores principales: Hejabi, Faranak, Abbaszadeh, Mohammad Sadegh, Taji, Shirinsadat, O’Neill, Andrew, Farjadian, Fatemeh, Doroudian, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450496/
https://www.ncbi.nlm.nih.gov/pubmed/36092658
http://dx.doi.org/10.3389/fchem.2022.957572
_version_ 1784784534391226368
author Hejabi, Faranak
Abbaszadeh, Mohammad Sadegh
Taji, Shirinsadat
O’Neill, Andrew
Farjadian, Fatemeh
Doroudian, Mohammad
author_facet Hejabi, Faranak
Abbaszadeh, Mohammad Sadegh
Taji, Shirinsadat
O’Neill, Andrew
Farjadian, Fatemeh
Doroudian, Mohammad
author_sort Hejabi, Faranak
collection PubMed
description In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery.
format Online
Article
Text
id pubmed-9450496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94504962022-09-08 Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems Hejabi, Faranak Abbaszadeh, Mohammad Sadegh Taji, Shirinsadat O’Neill, Andrew Farjadian, Fatemeh Doroudian, Mohammad Front Chem Chemistry In recent decades, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) has become one of the most promising genome-editing tools for therapeutic purposes in biomedical and medical applications. Although the CRISPR/Cas system has truly revolutionized the era of genome editing, the safe and effective delivery of CRISPR/Cas systems represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In addition, there are some challenges in the in vivo delivery to the targeted cells/tissues. Nanotechnology-based drug delivery systems can be employed to overcome this issue. This review discusses different types and forms of CRISPR/Cas systems and the current CRISPR/Cas delivery systems, including non-viral carriers such as liposomes, polymeric, and gold particles. The focus then turns to the viral nanocarriers which have been recently used as a nanocarrier for CRISPR/Cas delivery. Frontiers Media S.A. 2022-07-26 /pmc/articles/PMC9450496/ /pubmed/36092658 http://dx.doi.org/10.3389/fchem.2022.957572 Text en Copyright © 2022 Hejabi, Abbaszadeh, Taji, O’Neill, Farjadian and Doroudian. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Hejabi, Faranak
Abbaszadeh, Mohammad Sadegh
Taji, Shirinsadat
O’Neill, Andrew
Farjadian, Fatemeh
Doroudian, Mohammad
Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title_full Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title_fullStr Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title_full_unstemmed Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title_short Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems
title_sort nanocarriers: a novel strategy for the delivery of crispr/cas systems
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450496/
https://www.ncbi.nlm.nih.gov/pubmed/36092658
http://dx.doi.org/10.3389/fchem.2022.957572
work_keys_str_mv AT hejabifaranak nanocarriersanovelstrategyforthedeliveryofcrisprcassystems
AT abbaszadehmohammadsadegh nanocarriersanovelstrategyforthedeliveryofcrisprcassystems
AT tajishirinsadat nanocarriersanovelstrategyforthedeliveryofcrisprcassystems
AT oneillandrew nanocarriersanovelstrategyforthedeliveryofcrisprcassystems
AT farjadianfatemeh nanocarriersanovelstrategyforthedeliveryofcrisprcassystems
AT doroudianmohammad nanocarriersanovelstrategyforthedeliveryofcrisprcassystems